Piper Sandler raised the firm’s price target on Gilead (GILD) to $110 from $105 and keeps an Overweight rating on the shares after the company reported FY24 earnings and provided FY25 guidance. The firm notes the FY25 guide was solid, with the topline expected to see demand offset multiple headwinds and meaningful margin expansion with control of operating expenses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $120 from $105 at Wells Fargo
- Gilead Sciences: Balancing Strong HIV Franchise Performance with Cautious Outlook
- Gilead Sciences Reports Strong 2024 Financial Performance
- Gilead Sciences: Strong Financial Performance and Promising Future Prospects Justify Buy Rating
- Closing Bell Movers: Upstart jumps 24%, Lyft slip 9% on earnings